Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.

Gajiwala KS, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S, Kath JC, Stewart A.

Structure. 2013 Feb 5;21(2):209-19. doi: 10.1016/j.str.2012.11.014. Epub 2012 Dec 27.

2.

Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.

Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, Terazawa Y, Wakiyama M, Sato M, Sano S, Kobayashi T, Tanaka T, Chen L, Liu ZJ, Wang BC, Shirouzu M, Kawa S, Semba K, Yamamoto T, Yokoyama S.

Oncogene. 2013 Jan 3;32(1):27-38. doi: 10.1038/onc.2012.21. Epub 2012 Feb 20.

PMID:
22349823
3.

[Indication of EGFR kinase inhibitors should be refined].

Heneberg P.

Klin Onkol. 2011;24(2):87-93. Review. Czech.

PMID:
21644362
4.

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.

Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP.

Mol Cancer Ther. 2009 Aug;8(8):2142-51. doi: 10.1158/1535-7163.MCT-08-1219. Epub 2009 Aug 11.

5.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER.

Cancer Res. 2008 Jan 15;68(2):571-9. doi: 10.1158/0008-5472.CAN-07-2404.

6.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2006 Nov 1;12(21):6494-501.

7.

Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.

Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, Shavrin A, Soghomonyan S, Flores L 2nd, Young D, Volgin AY, Najjar AM, Krasnykh V, Tong W, Alauddin MM, Gelovani JG.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1603-8. doi: 10.1073/pnas.1010744108. Epub 2011 Jan 10.

8.

Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain.

Rosell R, Morán T, Carcereny E, Quiroga V, Molina MA, Costa C, Benlloch S, Tarón M.

Clin Transl Oncol. 2010 Feb;12(2):75-80. doi: 10.1007/S12094-010-0473-0. Review.

PMID:
20156777
9.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

10.

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44.

11.

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H.

PLoS Med. 2005 Mar;2(3):e73. Epub 2005 Feb 22.

12.

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.

Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.

13.

A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.

Lin WH, Song JS, Lien TW, Chang CY, Wu SH, Huang YW, Chang TY, Fang MY, Yen KJ, Chen CH, Chu CY, Hsieh HP, Chen YR, Chao YS, Hsu JT.

Anticancer Res. 2012 Jan;32(1):147-51.

PMID:
22213300
14.

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.

Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J.

Cancer Res. 2007 Mar 1;67(5):2325-30.

16.

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.

Tokumo M, Toyooka S, Ichihara S, Ohashi K, Tsukuda K, Ichimura K, Tabata M, Kiura K, Aoe M, Sano Y, Date H, Shimizu N.

Lung Cancer. 2006 Jul;53(1):117-21. Epub 2006 May 30.

PMID:
16730855
17.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. Epub 2005 May 16.

18.

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Jänne PA.

Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. doi: 10.1016/S0169-5002(08)70099-0. Review.

PMID:
18513582
19.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

20.

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.

Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.

J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16.

PMID:
20552223

Supplemental Content

Support Center